PALD1

Across TCGA pan-cancer cohorts, PALD1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PALD1 data layer compared with 26 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PALD1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PALD1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, COAD, and CCRCC are the cancer types where PALD1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	III,IV	0.922	0.292	.001	19	view →
COAD	DFS	Median	IV	0.565	1.000	.028	6	view →
CCRCC	DFS	Tertile	III,IV	0.719	0.405	.015	3	view →
LUAD	DFS	Quartile	All	0.842	0.519	.009	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PALD1–PDAC (DFS)

Open the PDAC breakdown →